Jon P. Stonehouse
Net Worth

Last updated:

What is Jon P. Stonehouse net worth?

The estimated net worth of Mr. Jon P. Stonehouse is at least $37,362,966 as of 13 May 2024. He owns shares worth $9,258,992 as insider, has earned $7,943,974 from insider trading and has received compensation worth at least $20,160,000 in BioCryst Pharmaceuticals, Inc..

What is the salary of Jon P. Stonehouse?

Mr. Jon P. Stonehouse salary is $1,120,000 per year as Chief Executive Officer, Pres & Executive Director in BioCryst Pharmaceuticals, Inc..

How old is Jon P. Stonehouse?

Mr. Jon P. Stonehouse is 64 years old, born in 1961.

What stocks does Jon P. Stonehouse currently own?

As insider, Mr. Jon P. Stonehouse owns shares in one company:

Company Title Shares Price per share Total value
BioCryst Pharmaceuticals, Inc. (BCRX) Chief Executive Officer, Pres & Executive Director 1,127,770 $8.21 $9,258,992

What does BioCryst Pharmaceuticals, Inc. do?

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BCRX logo
BCRX
BioCryst Pharmaceuticals, Inc.
$8.21

Jon P. Stonehouse insider trading

BioCryst Pharmaceuticals, Inc.

Mr. Jon P. Stonehouse has made 9 insider trades between 2007-2024, according to the Form 4 filled with the SEC. Most recently he purchased 30,000 units of BCRX stock worth $166,500 on 13 May 2024.

The largest trade he's ever made was exercising 214,917 units of BCRX stock on 1 Dec 2022. As of 13 May 2024 he still owns at least 1,127,770 units of BCRX stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 30,000 $5.55 $166,500
Option
Emp. Stock Option (Right to Buy) 31,055 $3.22 $99,997
Option
Common Stock 31,055 $3.22 $99,997
Option
Common Stock 100,000 $5.45 $545,000
Option
Emp. Stock Option (Right to Buy) 100,000 $5.45 $545,000
Sale
Common Stock 100,000 $10.38 $1,038,000
Sale
Common Stock 14,100 $10.9 $153,690
Option
Common Stock 82,656 $1.42 $117,372
Option
Emp. Stock Option (Right to Buy) 82,656 $1.42 $117,372
Sale
Common Stock 82,656 $12.8 $1,057,997
Option
Emp. Stock Option (Right to Buy) 214,917 $1.42 $305,182
Sale
Common Stock 214,917 $13 $2,793,921
Option
Common Stock 214,917 $1.42 $305,182
Sale
Common Stock 184,000 $15.04 $2,767,360
Option
Emp. Stock Option (Right to Buy) 184,000 $4.73 $870,320
Option
Common Stock 184,000 $4.73 $870,320
Sale
Common Stock 134,278 N/A N/A
Option
Emp. Stock Option (Right to Buy) 134,278 N/A N/A
Option
Common Stock 134,278 N/A N/A
Purchase
Common Stock 50,000 $1.45 $72,500
Sale
Common Stock 80,000 $1.2 $96,000
Option
Emp. Stock Option (Right to Buy) 80,000 $1.2 $96,000
Option
Common Stock 80,000 $1.2 $96,000
Option
Common Stock 70,427 $1.42 $100,006
Option
Emp. Stock Option (Right to Buy) 70,427 $1.42 $100,006
Option
Common Stock 56,949 $3.26 $185,654
Option
Emp. Stock Option (Right to Buy) 56,949 $3.26 $185,654
Option
Emp. Stock Option (Right to Buy) 24,096 $4.15 $99,998
Option
Common Stock 24,096 $4.15 $99,998
Option
Emp. Stock Option (Right to Buy) 33,868 $11.81 $399,981
Option
Common Stock 33,868 $11.81 $399,981
Option
Emp. Stock Option (Right to Buy) 20,000 $1.2 $24,000
Option
Common Stock 20,000 $1.2 $24,000
Sale
Common Stock 20,000 $1.2 $24,000
Option
Emp. Stock Option (Right to Buy) 30,792 $4.97 $153,036
Option
Common Stock 40,417 $4.7 $189,839
Option
Stock Option (Right to Buy) 9,625 $4.15 $39,944
Option
Common Stock 179,600 $1.2 $215,520
Option
Emp. Stock Option (Right to Buy) 179,600 $1.2 $215,520
Sale
Common Stock 2,721 $4.78 $13,006
Purchase
Common Stock 10,000 $2.52 $25,190
Purchase
Common Stock 10,000 $3.4 $33,990
Purchase
Common Stock 3,000 $1.62 $4,845
Purchase
Common Stock 55,000 $1.48 $81,455
Purchase
Common Stock 25,000 $1.75 $43,625
Purchase
Common Stock 2,300 $3.1 $7,125
Purchase
Common Stock 7,700 $2.95 $22,738
Purchase
Common Stock 240 $2.82 $677
Purchase
Common Stock 3,000 $3.5 $10,506
Purchase
Common Stock 2,650 $9.86 $26,129
Purchase
Common Stock 7,250 $9.87 $71,529
Purchase
Common Stock 2,463 $7.06 $17,376

BioCryst Pharmaceuticals key executives

BioCryst Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: